

Takahiro Kasamatsu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7512692/publications.pdf>

Version: 2024-02-01

12
papers

130
citations

1307594

7
h-index

1281871

11
g-index

18
all docs

18
docs citations

18
times ranked

177
citing authors

#	ARTICLE	IF	CITATIONS
1	Large volume was associated with increased risk of acute non-hematologic adverse events in the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer: preliminary results of prospective phase I/II clinical trial. Japanese Journal of Clinical Oncology, 2022, 52, 859-868.	1.3	4
2	On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity. Redox Biology, 2021, 41, 101926.	9.0	20
3	Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy. BMC Cancer, 2020, 20, 1169.	2.6	4
4	Dummy-run for standardizing plan quality of intensity-modulated radiotherapy for postoperative uterine cervical cancer: Japan Clinical Oncology Group study (JCOG1402). Radiation Oncology, 2019, 14, 133.	2.7	8
5	Single-arm confirmatory trial of postoperative concurrent chemoradiotherapy using intensity modulated radiation therapy for patients with high-risk uterine cervical cancer: Japan Clinical Oncology Group study (JCOG1402). Japanese Journal of Clinical Oncology, 2019, 49, 881-885.	1.3	5
6	Identifying selection criteria for non-radical hysterectomy in FIGO stage IB cervical cancer. Journal of Obstetrics and Gynaecology Research, 2019, 45, 882-891.	1.3	8
7	A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m ² cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors. International Journal of Clinical Oncology, 2019, 24, 575-582.	2.2	10
8	Determination of eligibility criteria for salvage hysterectomy after definitive radiotherapy/concurrent chemoradiotherapy for residual cervical disease.. Journal of Clinical Oncology, 2019, 37, 5524-5524.	1.6	1
9	Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study. Gynecologic Oncology, 2018, 148, 139-146.	1.4	41
10	Propensity score-matched analysis of systemic chemotherapy versus hysterectomy for patients with residual cervical disease after definitive radiotherapy/concurrent chemoradiotherapy.. Journal of Clinical Oncology, 2018, 36, 5527-5527.	1.6	0
11	Minimization of curative surgery for treatment of early cervical cancer: a review. Japanese Journal of Clinical Oncology, 2015, 45, 611-616.	1.3	17
12	Non-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer: Japan Clinical Oncology Group Study (JCOG1101). Japanese Journal of Clinical Oncology, 2015, 45, 123-126.	1.3	11